Benlysta® (belimumab) Intravenous Injection

Intravenous belimumab (Benlysta) is covered for patients ≥5 years with active systemic lupus erythematosus or active, biopsy‑confirmed lupus nephritis when used with standard therapy. Coverage requires autoantibody‑positive SLE (ANA and/or anti‑dsDNA), concurrent standard therapy or documented intolerance (for lupus nephritis, concurrent immunosuppression and biopsy confirmation), prescribing by or in consultation with an appropriate specialist, 12‑month authorizations with renewal contingent on documented clinical response, and adherence to the 10 mg/kg dosing schedule.

"Benlysta is indicated for the treatment of patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy."

Sign up to see full coverage criteria, indications, and limitations.